Bright Minds Biosciences Inc. (DRUG)
- GlobeNewswire
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Alan Kozikowski will no longer serve in the role of Chief Scientific Officer. “Alan has been with Bright Minds since the beginning, and his leadership was instrumental in shaping our
- GlobeNewswire
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that the Company will host a symposium with Key Opinion Leaders on Dravet Synd
- GlobeNewswire
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties
-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry, addiction, behavioral health, and pharmacology to guide Company’s development programs -- --Scientific Advisory Board members are affiliated with cutting-edge programs at elite academic and medical institutions -- -- Jan Torleif Pedersen, PhD, MSc, CNS drug specialist, to join Board of Directors -- V
